Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Alex Shimmings
Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijen.
The Pharmaceutical and Biotech industries’ R&D performance can be measured in a number of ways. Here is a look at its worldwide output of novel drug launches for 2016 and total pipeline size in 2017.
New Phase III data for the novel osteoporosis therapy romosozumab are set to delay its approval, reduce its commercial potential and open the market to rivals.
The Danish speciality dermatology company LEO Pharma has achieved a key plank in its plans to provide products for the range of psoriasis patients with an EU go-ahead for brodalumab.
Makers of novel oral anticoagulants need to work on gaining real world data to prove their worth to European payers, as their INR testing benefit gets lost in administration.
While most eyes were on AstraZeneca's keenly awaited MYSTIC lung cancer study of Imfinzi, its PACIFIC trial has ducked under the radar and hit investors with the nicest kind of surprise. The results could have wider implications for IO in earlier-stage cancers.